[Infographics] DESTINY-Gastric04: Superior OS with 2L T-DXd in HER2+ metastatic GC/GEJA

As a confirmatory trial building on DESTINY-Gastric02, the phase III DESTINY-Gastric04 trial showed OS benefits with T-DXd vs standard 2L treatment with ramucirumab plus paclitaxel in patients with HER2+ metastatic GC/GEJA, including the Asia subgroup.